CA2723232C — 5-hydroxymethyl-oxazolidin-2-one derivatives for treating bacterial intestinal diseases
Assigned to Actelion Pharmaceuticals Ltd · Expires 2016-08-02 · 10y expired
What this patent protects
The invention relates to the compounds of formula I (I) wherein A is N or CH; and n is 0 or 1; or the pharmaceuti-cally acceptable salts thereof, for preventing or treating intestinal diseases which are caused by bacteria selected from Clostridium difficile, Clostridium perfring…
USPTO Abstract
The invention relates to the compounds of formula I (I) wherein A is N or CH; and n is 0 or 1; or the pharmaceuti-cally acceptable salts thereof, for preventing or treating intestinal diseases which are caused by bacteria selected from Clostridium difficile, Clostridium perfringens or Staphylococcus aureus.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.